

**AXIM BIOTECH TO PRESENT AT EXCIPIENTFEST 2017  
IN PROVIDENCE, RHODE ISLAND**

**NEW YORK – April 26, 2017 – [AXIM® Biotechnologies, Inc.](#)** (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that Lekhram Changoer, Chief Technology Officer of AXIM Biotech, will deliver keynote presentation at the upcoming ExcipientFest 2017, to be held from April 25-26, 2017 at The Rhode Island Convention Center (RICC) in Providence, RI.

Mr. Changoer will present on formulation challenges surrounding the pharmaceutical use of cannabinoids and AXIM's patented extraction and micro-encapsulation technologies, which preserve high THC integrity while enhancing API stability and bioavailability for pharmaceutical preparations.

**Keynote presentation:** Medical Marijuana: Improving Stability with Novel Delivery Method

**Date and Time:** 03:30 PM to 04:15 PM ET

**Location:** 5F RICC

ExcipientFest attracts pharmaceutical scientists from around the world to a two-day forum for the latest scientific developments. ExcipientFest features in-depth technical talks on Excipient Technology, New Drug Applications and Regulatory Issues from industry's top-pharmaceutical experts. For more information about this conference, please visit: <http://www.excipientfest.com>.

###

**About AXIM®**

AXIM® Biotechnologies, Inc. (OTC: [AXIM](#)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum containing 10 mg of industrial hemp-derived CBD, CanChew Plus® (50 mg of CBD) undergoing clinical trials in patients with IBS, MedChew Rx®, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis and a number of other pharmaceutical, nutraceutical, cosmetic and consumer products in development. We prioritize the well-being of our customers while embracing a solid fiscal strategy and respect for the environment. For more information, please visit [www.AXIMBiotech.com](http://www.AXIMBiotech.com).

**FORWARD-LOOKING DISCLAIMER**

*This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and*

*uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.*

#### **LEGAL DISCLOSURE**

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

#### **Public Relations Contact**

##### **Andrew Hard**

Chief Executive Officer

CMW Media

[andrew.hard@cmwmedia.com](mailto:andrew.hard@cmwmedia.com)

P. +1888 829-0070

[www.cmwmedia.com](http://www.cmwmedia.com)

#### **Investor Relations Contact**

##### **Shiwei Yin, Grayling**

[Shiwei.Yin@grayling.com](mailto:Shiwei.Yin@grayling.com)

P. +1646 284-9474

##### **Lucia Domville, Grayling**

[lucia.domville@grayling.com](mailto:lucia.domville@grayling.com)

P. +1646 284-9416

#### **Corporate Contact Info**

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227